Have We Understood Diabetes? New Tasks for Diagnosis and Therapy

Abstract

Recently published data examining the role of the metabolic syndrome and obesity in cardiovascular disease rendered suprising results. In addition, other studies revealed that there is more to diabetes therapy than lowering blood glucose, which might under certain circumstances even harm patients. In the light that we now know that “death” is as important an endpoint in diabetes as in other diseases, new tools – better than the oral glucose tolerance test – are required to identify the patients at risk, as are additional standards in individualized therapy. A critical view on old concepts is necessary.

Key words

diabetes - therapy - diagnosis

References

• 1 The DECODE study group. . Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria.  Lancet. 1999;  354 617-621
• 2 Shepherd J, Blauw GJ, Murphy MB. et al . Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial.  Lancet. 2002;  360 ((9346)) 1623-1630
• 3 Shaper AG, Pocock SJ, Walker M. et al . British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns.  Br Med J (Clin Res Ed). 1981;  283 ((6285)) 179-186
• 4 Li G, Zhang P, Wang J. et al . The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study.  Lancet. 2008;  371 ((9626)) 1783-1789
• 5 Gaede P, Vedel P, Parving HH. et al . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study.  Lancet. 1999;  353 ((9153)) 617-622
• 6 Khaw K-T, Wareham N, Luben R. et al . Glycated hemoglobin, diabetes and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition.  Brit Med J. 2001;  322 1-6
• 7 Al Snih S, Ottenbacher KJ, Markides KS. et al . The Effect of Obesity on Disability vs Mortality in Older Americans.  Arch Intern Med. 2007;  167 774-780
• 8 Borch-Johnsen K, Colagiuri S. Diagnosing diabetes – time for a change?.  Diabetologia. 2009;  52 2247-2250
• 9 The International Expert Committee. . International expert committee report on the role of the HbA1c assay in the diagnosis of diabetes.  Diabetes Care. 2009;  32 1327-1334
• 10 Colagiuri S, Borch-Johnsen K. Detect-2: Early detection of type 2 diabetes and IGT.  Diabetes Voice. 2003;  48 11-13
• 11 Sabanayagan C, Liew G, Tai ES. et al . Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut off point for the diagnosis of diabetes?.  Diabetologia. 2009;  52 1279-1289
• 12 Myint PK, Sinha S, Wareham NJ. et al . Glycated haemoglobin and risk of stroke in people without known diabetes in the European prospective investigation into cancer (EPIC)-Norfolk prospective population study.  Stroke. 2007;  38 271-275
• 13 Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?.  Diabetologia. 2009;  52 1219-1226
• 14 Turnbull FM, Abraira C, Anderson RJ. et al . Intensive glucose control and macrovascular outcomes in type 2 diabetes.  Diabetologia. 2009;  52 2288-2298
• 15 Ray KK, Seshasai SR, Wijesuriya S. et al . Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.  Lancet. 2009;  373 1765-1772

Correspondence